Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1993-5-24
|
| pubmed:abstractText |
This paper summarizes results of rhuEPO--treatment obtained by different authors in 27 patients with a myelodysplastic syndrome (MDS). Only 1/3 of all patients with a MDS were responsive to rhuEPO treatment, while in 2/3 of these subjects no amelioration of anaemia was noticed, even after extremely high doses of this hormone. A detailed description of a patient with MDS, which was observed by the authors, is presented. In this patient the anaemia was refractive even after very high doses of rhuEPO administered for 10 weeks.
|
| pubmed:language |
pol
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0032-3772
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
88
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
451-7
|
| pubmed:dateRevised |
2010-4-1
|
| pubmed:meshHeading | |
| pubmed:year |
1992
|
| pubmed:articleTitle |
[Efficacy of recombinant human erythropoietin (rhuEPO) in treatment of anemia in patients with myelodysplastic syndrome].
|
| pubmed:affiliation |
Katedry i Kliniki Nefrologii Sl. AM, Katowicach.
|
| pubmed:publicationType |
Journal Article,
English Abstract,
Case Reports
|